The Senate Just Called the FDA a "Roadblock." Rare Disease Biotechs Are Watching.
The Senate titled its FDA hearing "From Regulator to Roadblock" and brought in biotech CEOs and patient advocates to make the case. With fresh legislation already reshaping orphan drug exclusivity and a $243 billion market at stake, rare disease biotechs are paying very close attention.
A Hearing Title That Tells You Everything
When the U.S. Senate titles a hearing "From Regulator to Roadblock: How FDA Bureaucracy Stifles Innovation," they're not exactly being subtle. That was the scene on February 26, when the Senate Special Committee on Aging hauled in patient advocates, doctors, and a biotech CEO to grill the FDA's approach to rare disease drug approvals.
The hearing, led by Chairman Rick Scott (R-FL) and Ranking Member Kirsten Gillibrand (D-NY), follows a November 2025 bipartisan letter the pair sent to FDA Commissioner Dr. Martin Makary. Their message: rare disease patients are waiting too long, and the FDA's review process is part of the problem.
For the hundreds of small biotechs building their entire business around orphan drugs (treatments for diseases affecting fewer than 200,000 Americans), this hearing could be the opening act of something much bigger.
The Witnesses Had Receipts
The panel wasn't stacked with bureaucrats reading prepared statements. It featured people with skin in the game:
Annie Kennedy, Chief Mission Officer of the EveryLife Foundation for Rare Diseases
Dr. Jeremy Schmahmann, Founding Director of the Massachusetts General Hospital Ataxia Center
Bradley Campbell, CEO of Amicus Therapeutics
Dr. Cara O'Neill, Co-Founder and Chief Science Officer of the Cure Sanfilippo Foundation
The testimony zeroed in on a familiar tension: the FDA has tools to speed things up, but it's not always using them. The 21st Century Cures Act, passed back in 2016, gave the agency a green light to use real-world evidence (data from actual patient outcomes, not just clinical trials) to evaluate drugs. Nearly a decade later, witnesses argued the FDA still isn't leaning into that flexibility enough for rare diseases.
Chairman Scott made clear he's not calling for the FDA to lower its safety standards. His critique was more targeted: delays are hurting patients, crushing small biotechs, and letting other countries eat America's lunch in biomedical innovation. He did praise Commissioner Makary's reform efforts, suggesting the hearing was more "nudge" than "attack."
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Why Rare Disease Is a Different Animal
To understand why the FDA's standard playbook struggles with rare diseases, think about sample sizes. If you're testing a heart drug, you can recruit 10,000 patients for a trial. If you're treating a condition that affects 500 people on Earth, good luck.
That math problem cascades through everything. Trials are smaller, slower, and more expensive per patient. Statistical significance is harder to prove. And the FDA's traditional review framework, built for common diseases with large datasets, can feel like trying to fit a kayak into a highway toll lane.
This is exactly where frameworks like the Rare Disease Evidence Principles (published in September 2025) come in. They push for more flexible endpoints, greater use of natural history data, and creative trial designs. But advocacy groups argue adoption has been sluggish.
Congress Already Made One Big Move This Month
The hearing didn't happen in a vacuum. Just three weeks earlier, on February 3, President Trump signed the Consolidated Appropriations Act of 2026 into law. Tucked inside was the Mikaela Naylon Give Kids a Chance Act, which made two changes that rare disease biotechs have been begging for.
First, it fixed a legal mess around orphan drug exclusivity. Under the Orphan Drug Act, companies that develop a rare disease treatment get seven years of market exclusivity, meaning no one else can sell the same drug for the same condition. It's one of the biggest incentives in the game.
But a 2021 court ruling (Catalyst Pharms., Inc. v. Becerra) blew the definition wide open. The court said exclusivity covered an entire rare disease, not just the specific use a drug was approved for. Imagine getting a patent on "pizza" when you only invented a new kind of pepperoni. That broader interpretation scared companies away from developing new uses within the same disease.
The new law narrows the language back to "same approved use or indication within such rare disease or condition," restoring the FDA's original, more practical interpretation. It applies retroactively, so the agency will need to review every active orphan exclusivity on its books.
Second, the law extended the Rare Pediatric Disease Priority Review Voucher program through September 2029. These vouchers are golden tickets: a company that gets a rare pediatric disease drug approved earns a voucher that shaves FDA review time from ten months down to six. The kicker? You can sell the voucher to anyone. Historically, they've traded for $65 million to $350 million, with $100 million being a common price tag. For a small biotech burning cash, that's the difference between life and death.
The Numbers Tell a Bigger Story
Rare disease isn't some niche corner of pharma anymore. It is pharma.
In 2025, the FDA approved 46 novel drugs. More than half carried orphan designations. That ratio has been climbing steadily; it was 52% in 2024 and 51% in 2023. The FDA now hands out over 400 orphan drug designations every year, and the global orphan drug market is projected to hit $243 billion in 2026, growing at roughly 12% annually.
Yet here's the paradox: of the estimated 7,000 to 10,000 rare diseases out there, 95% still have no approved treatment. The market is enormous and barely scratched.
Orphan drugs also succeed at roughly double the rate of non-orphan drugs in development (25-30% vs. 10-12%), partly because the FDA's flexible pathways and smaller trial requirements reduce risk. That success rate, combined with seven years of exclusivity and premium pricing, explains why every major pharma company now has a rare disease strategy.
What Happens Next
The hearing invited public statements through March 5, 2026, suggesting this committee isn't done. And less than a week before the hearing, on February 23, the FDA itself released a draft guidance on accelerating individualized therapies for ultra-rare diseases (conditions affecting fewer than one in a million people). That's the agency signaling it knows the current system isn't working for the rarest of the rare.
For biotech investors and founders, the signal from Washington is surprisingly clear, and surprisingly bipartisan. Both parties want faster rare disease approvals. The legislative fixes in the CAA address the biggest legal headaches. And the FDA is at least gesturing toward reform.
The real question is execution. Congress can hold hearings and write laws all day. But if the FDA doesn't change how reviewers apply the rules on the ground, patients with ultra-rare diseases will keep waiting. And for many of them, waiting isn't an option.
The committee's title may have been provocative, but the underlying frustration is real. When your kid has a disease that affects a few hundred people, and a promising therapy is stuck in regulatory limbo, "roadblock" is exactly the word you'd use too.
Deals & M&A4 min read
Gilead Just Paid $7.8B for a Protein the Size of a Paperclip
Gilead is spending $7.8 billion to acquire Arcellx and its next-gen CAR-T therapy for multiple myeloma. The secret weapon? A synthetic protein one-third the size of what competitors use, with clinical data that might just be best-in-class.
